

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-A**

---

**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES  
PURSUANT TO SECTION 12(b) OR (g) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

---

**Omega Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or incorporation or organization)

**81-3247585**  
(IRS Employer Identification No.)

**20 Acorn Park Drive,  
Cambridge, MA 02140**  
(Address of Principal Executive Offices)

**02140**  
(Zip Code)

**Securities to be registered pursuant to Section 12(b) of the Act:**

Title of each class  
to be so registered  
**Common Stock, \$0.001 par value per share**

Name of each exchange on which  
each class is to be registered  
**The Nasdaq Stock Market LLC**

---

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box.

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box.

**Securities Act registration statement file number to which this form relates:  
333-257794.**

**Securities to be registered pursuant to Section 12(g) of the Act:  
None.**

---

---

---

## INFORMATION REQUIRED IN REGISTRATION STATEMENT

### **Item 1. Description of Registrant's Securities to be Registered.**

The description of the Common Stock, par value \$0.001 per share, of Omega Therapeutics, Inc. (the "Registrant") under the heading "Description of Capital Stock" in the prospectus included in the Registrant's Registration Statement on Form S-1 (File No. 333-257794), as initially filed with the Securities and Exchange Commission on July 9, 2021, including exhibits, and as may be subsequently amended (the "Registration Statement"), is hereby incorporated by reference. Any form of prospectus that constitutes part of the Registration Statement and is subsequently filed by the Registrant pursuant to Rule 424(b) under the Securities Act of 1933, as amended, shall be deemed to be incorporated by reference herein.

### **Item 2. Exhibits.**

Pursuant to the Instructions as to Exhibits for Form 8-A, no exhibits are required to be filed because no other securities of the Company are registered on The Nasdaq Stock Market LLC, and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

**SIGNATURES**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

Date: July 26, 2021

**Omega Therapeutics, Inc.**

By: /s/ Mahesh Karande

Name: Mahesh Karande

Title: President and Chief Executive Officer